Celltrion Steps Up Global Partnering Push at CPHI 2026
Celltrion is stepping up efforts to broaden its global business portfolio beyond biosimilars, using the upcoming CPHI 2026 exhibition in Milan as a platform to pursue partnerships in novel drug development, contract manufacturing and pharmaceutical supply chains.The South Korean biopharmaceutical co
Celltrion is intensifying its global partnership initiatives at the upcoming CPHI 2026 exhibition in Milan, expanding beyond its biosimilar focus. The South Korean biopharmaceutical firm will take part in the three-day event from October 6 to 8, hosting a 46-pyeong booth with meeting rooms and a lounge. Celltrion aims to explore collaborations in novel drug development, contract manufacturing, and pharmaceutical supply chains.
The company plans to identify global partners in oncology, obesity, metabolic disorders, and autoimmune diseases to bolster its next-generation pipeline. In addition to biosimilars, Celltrion seeks to diversify its growth drivers by strengthening supply chain resilience and tapping into the growing demand for contract development and manufacturing organization (CDMO) services.
The exhibition, expected to gather over 60,000 industry professionals from more than 170 countries, will provide Celltrion with a platform to showcase its drug development and manufacturing capabilities and explore customized partnerships with global pharmaceutical companies.
Written by urgent.news from Korea IT Times's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
